İLHAN, Y. Et Al. 2022. Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER , vol.32, no.4 , 502-507.

İLHAN, Y., TATLI, A. M., Teker, F., Onder, A. H., Kose, F., Geredeli, C., ... KARAAĞAÇ, M.(2022). Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER , vol.32, no.4, 502-507.

İLHAN, YUSUF Et Al. "Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer," INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER , vol.32, no.4, 502-507, 2022

İLHAN, YUSUF Et Al. "Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer." INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER , vol.32, no.4, pp.502-507, 2022

İLHAN, Y. Et Al. (2022) . "Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer." INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER , vol.32, no.4, pp.502-507.

@article{article, author={YUSUF İLHAN Et Al. }, title={Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer}, journal={INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER}, year=2022, pages={502-507} }